Previous close | 10.29 |
Open | 11.20 |
Bid | 11.60 x 100 |
Ask | 14.18 x 200 |
Day's range | 10.36 - 16.40 |
52-week range | 3.35 - 16.40 |
Volume | |
Avg. volume | 866,686 |
Market cap | 650.661M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.38 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.67 |
BEDFORD, Mass., March 28, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
BEDFORD, Mass., March 26, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an addi